|
|
|
|
AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystro
Muscular Dystrophy / ALS News Main Category: Muscular Dystrophy / ALS email to a friend printer friendly view / write opinions Current Article Ratings: Patient / Public: 4.33 (3 votes) Health Professional: 5 (1 votes) Article Opinions:...
|
|
|
GSK forms new specialized R&D unit
GSK has established a new standalone unit specialising in the development and commercialisation of medicines for rare diseases Marc Dunoyer, president of Asia Pacific and chairman of Japan at GSK, is expected to lead the new operation, working closely with...
|
|
|
AVI BioPharma's drug candidate for Duchenne Muscular Dystrophy gets orphan drug designation from EMEA
_ AVI BioPharma's drug candidate for Duchenne Muscular Dystrophy gets orphan drug designation from EMEA.
|
|
|
Researchers Report That T4 Increases Skeletal Muscle And May Have A Role In The Treatment Of Duchenne Muscul
Regenerx Biopharmaceuticals, Inc.(NYSE Amex:RGN) announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with T4, showed a significant increase in skeletal muscle...
|
|
|
OGT Plans to Put New Consortium-Designed Arrays 'Forward First' to Cyto Customers
Oxford Gene Technology this week said it sees its new menu of International Standard Cytogenomic Array Consortium-designed microarrays as its top offering for the cytogenetics research community, which it said may favor the standardized arrays in an...
|
|
|
Avi obtains European orphan drug designation for genetic disorder drug
Avi BioPharma has received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency for AVI-5038, a drug candidate being developed by the company for the treatment of Duchenne muscular dystrophy, or...
|
|
|
TB4 increases skeletal muscle and may have role in treatment of Duchenne muscular dystrophy: Study
_ TB4 increases skeletal muscle and may have role in treatment of Duchenne muscular dystrophy: Study.
|
|
|
Hardee's(R) Kicks Off Fight Against Muscular Dystrophy in 2010
ROCKY MOUNT, NC -- (Marketwire) -- 02/08/10 -- Hardee's locations owned and operated by Boddie-Noell Enterprises (BNE) will raise funds this year for the Muscular Dystrophy Association by participating in the Shamrocks Against Dystrophy...
|
|
|
AVI BioPharmas Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy
AVI BioPharma, Inc., a developer of RNAbased drugs, announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency for AVI5038, a drug candidate being developed by AVI for the treatment of ...
|
|
|
Researchers Report That T4 Increases Skeletal Muscle And May Have A Role In The Treatment Of Duchenne Muscular Dystrophy
Regenerx Biopharmaceuticals, Inc.(NYSE Amex:RGN) announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with T4, showed a significant increase in skeletal muscle...
|
|
|
Medical News: Researchers Report That T4 Increases Skeletal Muscle And May Have A Role In The Treatment Of Duchenne Muscular Dystrophy
Regenerx Biopharmaceuticals, Inc.(NYSE Amex:RGN) announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with T4, showed a significant increase in skeletal muscle...
|
|
|
Researchers Report That T4 Increases Skeletal Muscle And May Have A Role In The Treatment Of Duchenne Muscul
Regenerx Biopharmaceuticals, Inc.(NYSE Amex:RGN) announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with T4, showed a significant increase in skeletal muscle...
|
|
|
GSK Launches Special Disease Unit
GlaxoSmithKline (GSK) has announced the formation of a new specialised unit to research and develop treatments for rare diseases.The new unit will leverage off strategic collaborations formed in 2009 with two specialist companies, Prosensa and JCR...
|
|
|
Hardee's(R) Kicks Off Fight Against Muscular Dystrophy in 2010
Hardee's@ locations owned and operated by Boddie-Noell Enterprises (BNE) will raise funds this year for the Muscular Dystrophy Association by participating in the Shamrocks Against Dystrophy campaign.Beginning Feb. 9 and ending March 17,...
|
|
|
AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne ...
AVI BioPharma announced that the results and scientific findings of Good Laboratory Practice (GLP)-compliant safety pharmacology and genotoxicity evaluations of AVI-4658, a drug candidate being developed by AVI for the treatment of Duchenne Muscular...
|
|
|
Medical News: AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy
AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI-5038, a drug candidate being developed by...
|
|
|
AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy
AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI-5038, a drug candidate being developed by...
|
|
|
GSK launches new specialist unit to research and develop medicines for rare diseases
GSK today announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases London, UK | February 4, 2010 | GSK today announces the formation of a new standalone unit specialising in the...
|
|
|
GSK Launches New Specialist Unit To Research And Develop Medicines For Rare Diseases
GSK announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases.Over 5,500 rare diseases have been identified(1) of which less than 10% are currently being treated(2), presenting a...
|
|
|
Repligen Reports Third Quarter Fiscal Year 2010 Financial Results
WALTHAM, Mass., Feb.4 /PRNewswire-FirstCall/ -- Repligen Corporation ( NASDAQ:RGEN) today reported results for the third quarter of fiscal year 2010, ended December 31, 2009. Total revenue for the quarter was $5,617,000 compared to total revenue of $6,018...
|
|
|
Let's start ALS clinic in Asheville, help extend lives
I will live nine months longer than the average ALS patient because a multidisciplinary team of ALS specialists provides my care.They are some of my favorite people. Amber is an occupational therapist who gets me equipment to help with daily living. Amy...
|
|
|
AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation for Duchenne Muscular Dystro
AVI BioPharma, Inc., a developer of RNA-based drugs, today announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI-5038, a drug candidate being developed by AVI for the...
|
|
|
AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation for Duchenne Muscular Dystro
BOTHELL, WA (MARKET WIRE) 02/05/10 AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, today announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI...
|
|
|
AVI BioPharma's AVI-5038 receives European orphan drug designation
- US-based developer of RNA-based drugs AVI BioPharma Inc (NASDAQ: AVII) announced today that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMA) for AVI-5038, a drug candidate being...
|
|
|
T4 may help treat skeletal muscle disease in Duchenne muscular dystrophy
REGENERX BIOPHARMACEUTICALS, INC.(NYSE Amex:RGN) announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with T4, showed a significant increase in skeletal muscle...
|
